0941 GMT - Reckitt reported a mixed set of 2024 results as profits and earnings came considerably ahead of expectations but fourth-quarter sales put a slight damper on things, Quilter Cheviot head of equity research Chris Beckett says in a note. The consumer-goods company--which houses Dettol, Harpic and Durex among its brands--lifted profits through a gearing effect from higher prices and productivity improvements that led to a lower cost base, Beckett says. However, fourth-quarter sales were disappointing, reflecting the weak cold-and-flu season in the U.S. as reported by peers such as Kenvue and Procter & Gamble, he adds. Reckitt's 4Q sales growth came in at 4.6%, but the market was expecting 5.3%, Beckett adds. Shares are up 2% and have risen nearly 10% since the start of 2025. (michael.susin@wsj.com)
(END) Dow Jones Newswires
March 06, 2025 04:41 ET (09:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。